Evidence map›Paper›PMID 29674636›Full record

ArticleThe Journal of antibiotics2018

Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile.

Arun K Sharma, Jacek Krzeminski, Volkmar Weissig, John P Hegarty, David B Stewart

Abstract read
In one paragraph

Article in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Validation of Clinical Risk Models for Clostridioides difficileAntimicrobial agents and chemotherapy · 2022
    Article
  5. Opportunities for Nanomedicine inAntibiotics (Basel, Switzerland) · 2021
    Review
  6. Anti-virulence strategies forGut microbes · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Arun K SharmaDepartment of Pharmacology, College of Medicine, The Pennsylvania State University, Hershey, PA, 17033, USA.
Jacek KrzeminskiDepartment of Pharmacology, College of Medicine, The Pennsylvania State University, Hershey, PA, 17033, USA.
Volkmar WeissigDepartment of Pharmaceutical Sciences, Nanomedicine Center of Excellence, College of Pharmacy Midwestern University, Glendale, AZ, 85308, USA.
John P HegartyDepartment of Medicine, College of Medicine, The Pennsylvania State University, Hershey, PA, 17033, USA.ORCID http://orcid.org/0000-0003-3401-848X
David B StewartDepartment of Surgery, University of Arizona - Banner University Medical Center, Tucson, AZ, 85724, USA. dbstewart@surgery.arizona.edu.
Pennsylvania State University · USBanner - University Medical Center Tucson · USMidwestern University · US

Funding

Cationic Bolaamphiphiles (CAB) and Phosphorothioate Gapmers as Antisense Therapy for C. difficileR21AI132353 · NIAID · UNIVERSITY OF ARIZONA · PI SHARMA, ARUN K, STEWART, DAVID B. · 2017 to 2018
$422k
NIAID NIH HHS R21 AI132353
6 · The paper itself

Abstract

Conventional antibiotics for C. difficile infection (CDI) have mechanisms of action without organismal specificity, potentially perpetuating the dysbiosis contributing to CDI, making antisense approaches an attractive alternative. Here, three (APDE-8, CODE-9, and CYDE-21) novel cationic amphiphilic bolaamphiphiles (CABs) were synthesized and tested for their ability to form nano-sized vesicles or vesicle-like aggregates (CABVs), which were characterized based on their physiochemical properties, their antibacterial activities, and their toxicity toward colonocyte (Caco-2) cell cultures. The antibacterial activity of empty CABVs was tested against cultures of E. coli, B. fragilis, and E. faecalis, and against C. difficile by "loading" CABVs with 25-mer antisense oligonucleotides (ASO) targeting dnaE. Our results demonstrate that empty CABVs have minimal colonocyte toxicity until concentrations of 71 µM, with CODE-9 demonstrating the least toxicity. Empty CABVs had little effect on C. difficile growth in culture (MIC90 ≥ 160 µM). While APDE-8 and CODE-9 nanocomplexes demonstrated high MIC

Indexed as

Anti-Bacterial AgentsBacteroides fragilisCaco-2 CellsCell Line, TumorClostridioides difficileDysbiosisEnterococcus faecalisEnterocolitis, PseudomembranousEscherichia coliFuransHumansMicrobial Sensitivity TestsMicrobiotaOligonucleotides, AntisensePyridonesAnti-Bacterial AgentsbolaamphiphileFuransOligonucleotides, AntisensePyridones

Identifiers

PMID29674636
PMCPMC6063762
OpenAlexW2801816097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.